Skip to main content
. 2019 May 16;20:171. doi: 10.1186/s12882-019-1348-4

Fig. 2.

Fig. 2

(a) Patient distribution and (b) CKD stage distribution (where reported) across the study cohorts in the CKD population CKD chronic kidney disease, DKD diabetic kidney disease, ESRD end-stage renal disease, HF heart failure, MRA mineralocorticoid receptor antagonist